Arcturus Therapeutics Holdings Inc.
09/26/2025 | Press release | Distributed by Public on 09/26/2025 04:06
Meiji Seika Pharma Launches Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine, in Japan (Form 8-K)
Meiji Seika Pharma Launches Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine, in Japan
Meiji Seika Pharma Co., Ltd. (Headquarter: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it launched a new presentation of KOSTAIVE®, a self-amplifying mRNA vaccine against COVID-19, supplied in vials, each containing two doses.
The product targets the SARS-CoV-2 Omicron sublineage JN.1 variant XEC. In non-clinical studies, it induced neutralizing antibodies not only against Omicron JN.1 and XEC, but also against LP.8.1 and the currently circulating variants XFG and NB.1.8.1. The formulation is supplied as a two-dose vial, with one vial per carton.
Meiji Seika Pharma remains committed to contributing to the prevention of COVID-19.
About sa-mRNA
mRNA vaccines help protect against infectious diseases by providing a blueprint for cells in the body to make a protein to help our immune systems recognize and fight the disease. Compared to standard mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and spike protein to generate a more durable immune response
| Brand Name | KOSTAIVE intramuscular injection |
| Antigen strain | SARS-CoV-2 Omicron sublineage JN.1 variant XEC |
| Active ingredient | Coronavirus (SARS-CoV-2) self-amplifying mRNA vaccine |
| Use & Dosage |
Dissolve this drug in 1.5 mL of Japanese Pharmacopoeia physiological saline solution. Administer a single dose of 0.5 mL intramuscularly |
| Date of Manufacturing and Marketing Approval | August 28, 2025 |
| Date of Launch in Japan | September 26, 2025 |
| Packaging | 1 vial |
*For further information, please refer to the package insert.
Arcturus Therapeutics Holdings Inc. published this content on September 26, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 26, 2025 at 10:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]